🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Repeated Examinations for Typing Pulmonary Embolism

Recruitingn/aAges 18 Years - anyAllSahlgrenska University Hospital
NCT07491094 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

PURPOSE The two related purposes of the RE-TyPE study are: 1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and 2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital HYPOTHESES 1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome 2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital 2. Written informed consent Exclusion Criteria from Cohort A: 1. Low risk, intermediate-low risk or high risk PE\* 2. \>48 hours since PE diagnosis 3. Expected inability to comply with the protocol (e.g. dementia) Exclusion Criterium from Cohort B: 1\. Not geographically belonging to Sahlgrenska University Hospital \*If biomarkers (and/or echocardiography) are not available in hemodynamically stable patients, RV/LV-ratio \>1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B
💊

What it tests

  • Not listed
📍

Where

3 sites
Sahlgrenska University Hospital/Mölndal
Gothenburg, Sweden
Sahlgrenska University Hospital/Sahlgrenska
Gothenburg, Sweden
Sahlgrenska University Hospital/Östra
Gothenburg, Sweden
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy